GE HealthCare Technologies (GEHC) Stock Overview
Engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
GEHC Community Fair Values
Create NarrativeSee what 119 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
GE HealthCare Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$64.26 |
| 52 Week High | US$89.77 |
| 52 Week Low | US$58.75 |
| Beta | 0.87 |
| 1 Month Change | -13.34% |
| 3 Month Change | -22.59% |
| 1 Year Change | -7.65% |
| 3 Year Change | -16.03% |
| 5 Year Change | n/a |
| Change since IPO | 7.10% |
Recent News & Updates
Narrative Update • May 12
GEHC: AI Imaging And Segment Reorganization Will Support 2026 Repricing Potential
Analysts have trimmed the implied fair value for GE HealthCare Technologies to about $79.95 from roughly $90.74, as a series of firms reduced price targets and reset assumptions for growth, profitability and future P/E multiples following recent sector research updates. Analyst Commentary Recent research shows a cluster of target cuts and at least one target increase, with views splitting between confidence in GE HealthCare Technologies' execution since the separation from General Electric and caution around growth expectations and valuation multiples.Seeking Alpha • Apr 30
GE HealthCare: Soft Execution More Than Priced Accordingly
Summary GE HealthCare shares have fallen to $60 after a soft Q1 and guidance cut, now trading at the low end of their post-spin range. Q1 organic growth was 2.9%, below full-year targets, and EBIT margin guidance was trimmed, but valuation multiples have compressed to 12–13x earnings. Despite headwinds—tariffs, supplier issues, and rising costs—GE HealthCare maintains 3–4% organic growth guidance and is integrating the Intelerad acquisition for incremental EBITDA. I see long-term value as earnings yield rises to 8%, with potential upside from growth, buybacks, and margin expansion toward 20%. Read the full article on Seeking AlphaRecent updates
Narrative Update • May 12
GEHC: AI Imaging And Segment Reorganization Will Support 2026 Repricing Potential
Analysts have trimmed the implied fair value for GE HealthCare Technologies to about $79.95 from roughly $90.74, as a series of firms reduced price targets and reset assumptions for growth, profitability and future P/E multiples following recent sector research updates. Analyst Commentary Recent research shows a cluster of target cuts and at least one target increase, with views splitting between confidence in GE HealthCare Technologies' execution since the separation from General Electric and caution around growth expectations and valuation multiples.Seeking Alpha • Apr 30
GE HealthCare: Soft Execution More Than Priced Accordingly
Summary GE HealthCare shares have fallen to $60 after a soft Q1 and guidance cut, now trading at the low end of their post-spin range. Q1 organic growth was 2.9%, below full-year targets, and EBIT margin guidance was trimmed, but valuation multiples have compressed to 12–13x earnings. Despite headwinds—tariffs, supplier issues, and rising costs—GE HealthCare maintains 3–4% organic growth guidance and is integrating the Intelerad acquisition for incremental EBITDA. I see long-term value as earnings yield rises to 8%, with potential upside from growth, buybacks, and margin expansion toward 20%. Read the full article on Seeking AlphaNarrative Update • Apr 27
GEHC: AI Imaging And Clinical Trial Progress Will Support 2026 Repricing Potential
Analysts have trimmed the implied fair value for GE HealthCare Technologies by about $1 to $90.74 per share. This reflects a combination of recent price target reductions from several firms and updated assumptions that include a slightly higher discount rate, modestly adjusted revenue growth, and a somewhat lower future P/E multiple.
New Narrative • Apr 26
GE HealthCare (GEHC): The Precision Sentinel Braces for a High-Tech Margin Duel
GE HealthCare Technologies Inc. (GEHC) , the global vanguard of precision medicine and clinical visualization, enters the weekend of Sunday, April 26, 2026 , in a state of resilient transition.Narrative Update • Apr 11
GEHC: AI Imaging Advances Will Support 2026 Repricing Potential
The analyst price target for GE HealthCare Technologies has shifted slightly lower, with the model moving from about $93.47 to $91.74 as analysts factor in a mix of recent target cuts and raises across the Street, while sector fundamentals are described as healthy. Analyst Commentary Recent research updates on GE HealthCare Technologies show a mix of optimism and caution, with several firms adjusting price targets in both directions and at least one downgrade.Narrative Update • Mar 28
GEHC: AI Imaging And Procedure Recovery Will Support 2026 Repricing
Analysts have lifted the blended price target for GE HealthCare Technologies slightly, with the updated fair value estimate moving from about $93.05 to $93.47 as recent research cites healthy MedTech sector fundamentals, recovering end markets into 2026, and the company’s post spin execution as key supports, even as some firms trim targets within a volatile group. Analyst Commentary Street research around GE HealthCare Technologies presents a mix of optimism and caution, with several firms adjusting price targets following sector wide reviews and recent company updates.Narrative Update • Mar 13
GEHC: AI Workflow Gains In Healthy MedTech Sector Will Drive 2026 Repricing
Narrative Update on GE HealthCare Technologies The revised analyst price target for GE HealthCare Technologies edges down by $0.20 to $93.05. This reflects mixed Street views, as some firms trim targets while others lift them on what they describe as solid early post spin execution and broadly healthy MedTech sector fundamentals.Narrative Update • Feb 26
GEHC: AI Alliances And MedTech Rotation Risks Will Shape 2026 Repricing
Analysts have nudged their average $ price target on GE HealthCare higher by low single digits, pointing to slightly stronger revenue growth, modestly firmer profit margins, and fine-tuned discount rate and future P/E assumptions after a series of recent target increases across major firms alongside one downgrade. Analyst Commentary Recent research updates on GE HealthCare Technologies show a mix of enthusiasm and caution, with several firms fine tuning their price targets and one moving to a more conservative stance.Narrative Update • Feb 11
GEHC: AI Alliances And Hospital Equipment Spending Will Support 2026 Repricing
Analysts lifted their price target on GE HealthCare Technologies to $93.25 from $92, citing updated assumptions around revenue growth, profitability, discount rate, and future P/E that reflect a blend of recent target increases and one downgrade across the Street. Analyst Commentary Street research on GE HealthCare has been active, with several bullish price target adjustments and one downgrade.Analysis Article • Feb 07
GE HealthCare Technologies Inc. (NASDAQ:GEHC) Yearly Results: Here's What Analysts Are Forecasting For This Year
Investors in GE HealthCare Technologies Inc. ( NASDAQ:GEHC ) had a good week, as its shares rose 2.1% to close at...Narrative Update • Jan 27
GEHC: AI Partnerships And Hospital CapEx Support Constructive 2026 Setup
Analysts have nudged their fair value estimate for GE HealthCare Technologies slightly higher to $92.00, citing a series of recent price target increases and research highlighting steady organic growth expectations, constructive MedTech trends into 2026 and a generally healthy hospital CapEx backdrop despite at least one downgrade in the group. Analyst Commentary Recent Street research around GE HealthCare points to a mixed but generally constructive setup, with several firms lifting price targets while at least one has turned more cautious.Narrative Update • Jan 10
GEHC: Margin Execution And AI Imaging Pipeline Will Support Balanced 2026 Setup
Analysts have nudged their fair value estimate for GE HealthCare Technologies higher to $91.80, reflecting recently raised Street price targets and expectations that steady organic growth and margin execution could support a P/E closer to 20x over time. Analyst Commentary Recent Street research on GE HealthCare Technologies clusters around a constructive long term setup, with several firms lifting their price targets and focusing on execution through 2026.Narrative Update • Dec 16
GEHC: Mid-Term Margin Execution Will Offset China Uncertainty And Support Steady Outlook
Analysts have made a modest upward revision to their fair value estimate for GE HealthCare Technologies, nudging the implied price target fractionally higher to reflect improved confidence in demand trends and mid term margin execution, despite slightly lower projections for revenue growth and profit margins. Analyst Commentary Bullish analysts highlight that, even with near term estimate tweaks, the investment case increasingly rests on confidence in GE HealthCare's ability to deliver mid term margin expansion and steady organic growth.Narrative Update • Nov 22
GEHC: Order Backlog And Margin Expansion Will Drive Upside Despite China Risk
The analyst price target for GE HealthCare Technologies has increased modestly to $89.21 from $86.96, reflecting analysts' confidence in the company's achievable revenue growth, margin improvement, and a supportive overall demand environment, even though there are mixed views on near-term challenges. Analyst Commentary Recent analyst updates highlight a mix of confidence and caution regarding GE HealthCare Technologies' outlook.Narrative Update • Oct 15
New IDN Partnerships And Advanced Imaging Will Unlock Future Markets
Analysts have modestly lowered their price target for GE HealthCare Technologies from $88 to approximately $86.96 per share, citing incremental shifts in fair value and ongoing market uncertainties, such as evolving conditions in China and sustained concerns over order books. These factors are balanced by encouraging updates to the company’s product pipeline.Analysis Article • Aug 01
Results: GE HealthCare Technologies Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Shareholders might have noticed that GE HealthCare Technologies Inc. ( NASDAQ:GEHC ) filed its second-quarter result...Analysis Article • Jul 29
Should You Think About Buying GE HealthCare Technologies Inc. (NASDAQ:GEHC) Now?
GE HealthCare Technologies Inc. ( NASDAQ:GEHC ) saw a significant share price rise of 29% in the past couple of months...Analysis Article • Jul 16
GE HealthCare Technologies Inc.'s (NASDAQ:GEHC) Low P/E No Reason For Excitement
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Shareholder Returns
| GEHC | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 3.8% | 4.0% | -0.3% |
| 1Y | -7.6% | -18.6% | 26.7% |
Return vs Industry: GEHC exceeded the US Medical Equipment industry which returned -21.1% over the past year.
Return vs Market: GEHC underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| GEHC volatility | |
|---|---|
| GEHC Average Weekly Movement | 5.9% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: GEHC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GEHC's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 54,000 | Pete Arduini | www.gehealthcare.com |
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women’s health products.
GE HealthCare Technologies Inc. Fundamentals Summary
| GEHC fundamental statistics | |
|---|---|
| Market cap | US$28.01b |
| Earnings (TTM) | US$1.91b |
| Revenue (TTM) | US$20.98b |
15.3x
P/E Ratio1.4x
P/S RatioIs GEHC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GEHC income statement (TTM) | |
|---|---|
| Revenue | US$20.98b |
| Cost of Revenue | US$12.77b |
| Gross Profit | US$8.21b |
| Other Expenses | US$6.30b |
| Earnings | US$1.91b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.20 |
| Gross Margin | 39.14% |
| Net Profit Margin | 9.10% |
| Debt/Equity Ratio | 93.0% |
How did GEHC perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield3%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 04:47 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GE HealthCare Technologies Inc. is covered by 26 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Miksic | Barclays |
| Navann Ty Dietschi | BNP Paribas |
| Travis Steed | BofA Global Research |